Article Information
History
- September 1, 2022.
Article Versions
- You are currently viewing Version 1 of this article (September 1, 2022 - 15:03).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Manuela Di Fusco1,*,
- Xiaowu Sun2,
- Mary M. Moran3,
- Henriette Coetzer2,
- Joann M. Zamparo3,
- Laura Puzniak3,
- Mary B. Alvarez4,
- Ying P. Tabak2 and
- Joseph C. Cappelleri5
- 1Pfizer Inc., Health Economics and Outcomes Research, New York, NY, USA
- 2CVS Health, Woonsocket, RI, USA
- 3Pfizer Inc., MDSCA Vaccines, Collegeville, PA, USA
- 4Pfizer Inc., Field Medical Outcomes and Analytics, New York, NY, USA
- 5Pfizer Inc., Statistical Research and Data Science Center, Groton, CT, USA
- ↵*Corresponding author:
Manuela Di Fusco, Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA, Manuela.difusco{at}pfizer.com